|
A.F. Verbovoy, N.I. Verbovaya, L.A. Sharonova
Hypothyroidism is an untimely diagnosed disease
|
№11-12 / 2022
|
|
M.B. Antsiferov (1), O.M. Koteshkova (1), M.S. Novikova (1), N.A. Demidov (2)
Possibilities of dapagliflozin in cardio-reno-metabolic protection in patients with and without type 2 diabetes mellitus
|
№12 / 2021
|
|
A.F. Verbovoy, Yu.A. Dolgikh
Insulin resistance – a common enemy for endocrinologists and cardiologists
|
№12 / 2021
|
|
D.I. Trukhan, D.S. Ivanova
Role and location of increased epithelial permeability syndrome in the development of cardiovascular and bronchopulum diseases: theoretical and practical aspects of application of rebamipide
|
№5 / 2021
|
|
N.A. Karoli, A.P. Rebrov
Beta-blockers in patients with chronic obstructive pulmonary disease: for whom, when, how?
|
№5 / 2020
|
|
V.Ya. Dzerve
ENERGY METABOLISM CORRECTOR MILDRONATE®: INTERRELATION OF MECHANISMS OF ACTION AND THERAPEUTIC EFFECTS
|
№15 / 2017
|
|
M.A. Ayrapetyan, I.G. Gordeev, N.A. Volov
GENDER FEATURES OF ACUTE CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION
|
№9 / 2017
|
|
V.N. Shishkova
PROBLEMS OF COMORBID PATIENT AND POLYPRAGMASY IN NEUROLOGY
|
№9 / 2017
|
|
N.A. Petunina, A.L. Terekhova
ELDERLY PATIENT WITH TYPE 2 DIABETES MELLITUS: FOCUS ON ALOGLIPTIN
|
№5 / 2017
|
|
L.A. Sharonova, A.F. Verbovoy, I.A. Tsanava
STATE OF CARDIOVASCULAR SYSTEM IN METABOLIC SYNDROME
|
№5 / 2017
|
|
E.N. Shirokova
NONALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR RISK (LITERATURE REVIEW)
|
№2 / 2017
|
|
N.A. Shostak, A.A. Klimenko, D.A. Anichkov, A.A. Kondrashov
NEW MECHANISMS OF ACTION OF NSAIDS: FOCUS ON CARDIOVASCULAR SAFETY
|
№19 / 2016
|
Русский
